The Role of AI in Rare Disease Drug Discovery

AI, data-sharing, and gene technologies are peering into the future of rare disease drug development, and overcoming economic, regulatory, and diagnostic challenges for transformative therapies.

By
Dan Williams
February 6, 2026
11 min

The Medicine Maker

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Broad Institute of MIT and Harvard

Cambridge, MA
Key Differentiators
- Genomics
- Rare Disease Research
- Artificial Intelligence
- Drug Discovery
#2

Stanford University School of Medicine

Stanford, CA
Key Differentiators
- Artificial Intelligence
- Rare Disease Genomics
- Translational Medicine
#3

National Institutes of Health (NIH) - National Center for Advancing Translational Sciences (NCATS)

Bethesda, MD
Key Differentiators
- Rare Disease Research
- Translational Science
- Data Science
- Drug Development
#4

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Precision Medicine
- Rare Disease Therapeutics
- Artificial Intelligence
#5

University of California, San Francisco (UCSF) Medical Center

San Francisco, CA
Key Differentiators
- Rare Disease Research
- Genomics
- Artificial Intelligence
- Drug Development

The Role of AI in Rare Disease Drug Discovery

Top Institutions in Oncology

Broad Institute of MIT and Harvard

Stanford University School of Medicine

National Institutes of Health (NIH) - National Center for Advancing Translational Sciences (NCATS)

Dana-Farber Cancer Institute

University of California, San Francisco (UCSF) Medical Center

Original Source(s)

The Role of AI in Rare Disease Drug Discovery

Related Content

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease